ATLANTA, Feb. 22 /PRNewswire-FirstCall/ -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG) has received numerous inquiries regarding the temporary change of its symbol to "MDXGE.OB" rather than "MDXG.OB". This resulted from the change of the Company's fiscal year to a calendar year, as reported on form 8-K filed December 21, 2009. The matter has been resolved and the OTC:BB has advised the Company that its stock will resume trading under "MDXG.OB" on Tuesday, February 23. Until such time, as was the case today, the Company's shares may be traded using the temporary symbol.
About MiMedx Group, Inc.
MiMedx Group, Inc. is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and is in the process of transitioning from a development-focused concern to an operating company focused on sales growth and profitability. The Company's assets include intellectual property protecting a collagen-based technology for augmentation of soft and connective tissue diseases and trauma and intellectual property protecting a novel durable hydrogel technology. The Company has received FDA clearance for its first durable hydrogel product, the Paradis Vaso Shield ™ indicated for use as a cover for vessels following anterior spinal surgery.
Important Note regarding forward-looking statements and risk factors. This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. These statements include those regarding the date on which its shares will resume trading under its former symbol. These risks and uncertainties include that the resumption may be delayed due to administrative issues . The risks and uncertainties also include the risk factors detailed in its Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended March 31, 2009, and its most recent Form 10-Q filed on November 16, 2009. The Company does not undertake to update its forward-looking statements.
SOURCE MiMedx Group, Inc.Back to top
|SOURCE MiMedx Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved